Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. regarding potential securities fraud or unlawful business practices. The investigation follows Elicio's June 15, 2026 press release reporting that its Phase 2 AMPLIFY-7P Study did not meet the pre-specified primary endpoint of disease-free survival in the intent-to-treat population. On that news, Elicio's stock price fell $9.97 per share, or 70.96%, to close at $4.08 per share. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.
Elicio Therapeutics Inc.Phase 2 trial failed primary endpoint, causing 70.96% stock drop and triggering securities fraud investigation.